ADDAX
Acid Deprived DiAldehyde FiXative
ADDAX Biosciences is an academic spin-off of the University of Turin, born after long time research activity of its founders on the fixation of pathological tissues. Our company goal is to replace the use of Formalin (a cancerogenic and toxic solution of Formaldehyde) as a fixative solution, while preserving optimal tissue fixation to guarantee correct diagnosis and therapy.
MORE INFORMATIONS
Write us to learn more about GAF.
We believe it is necessary to guarantee the highest standard of accuracy and reliability of the examinations carried out on biological samples, in order to preserve the health of the patients. At the same time, we also deem necessary to safeguard the health of the operators.
Investor
Fabio Bellio
Purchasing & Supply Chain Manager at Ahlstrom Munksjo Italia
Financial Advisor
Sergio Traversa
PharmD, MBA, CEO of Relmada Therapeutics Inc.
Financial Advisor
Enrico Sorisio
Chartered accountant, business and tax consultant
Scientific Advisor
Manfred Dietel
Professor of Pathology
Director of Institute of Pathology, University Hospital Charitè, Berlin
Scientific Advisor
Giorgio Stanta
Professor of Pathology at the University of Trieste
Collaboration with the A.O.U. Città della Salute e della Scienza in Turin, for the “Glyoxal in Endoscopy” project.
Collaboration with the Zooprophylactic Institute in Turin for GAF’s use in the veterinary sector, especially concerning neurological pathology.
Collaboration with the University of Turin to improve research activity on the fixation of pathological tissues.
Collaboration with the University of Padova for GAF’s use as fixative in the veterinary sector.
Collaboration with the Candiolo Cancer Institute – IRCCS for the Immuno K-ELISA project and the study on the AD FORMALIN’s use.
Collaboration with the Dental School of University of Turin to develop innovative compounds capable to replace the use of Formaldehyde in Dentistry, particularly as disinfectant material during pulpotomy.
ADDAX Biosciences was born as a spin off of the University of Turin, which contribuited with support to the research activity.
Our company has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No 8157692.
The project “GAF – Towards a hospital without Formalin” is realized thanks to the co-financing of POR FESR Piemonte 2014-2020, Ob.1 – “Research, technological development and innovation, I.1.b.4.1 “Support for creation and consolidation of innovative start-ups with a high intensity of application and knowledge and research spin-off initiatives”.
The project aims to validate, produce and market GAF, a histological fixative without carcinogenicity, that works as a substitute to Formalin. Achieving the project’s objectives will improve the working conditions of health and research professionals, protecting them from the risk of developing occupational diseases caused by inhaling Formalin vapours.
